Business Standard

Mylan launches Remdesivir at Rs 4,800 for Covid patients in India

The company has also launched a 24x7 helpline using which patients and healthcare practitioners can access information about the drug and its availability

remdesivir, coronavirus, drugs, covid, pharma
Premium

Samreen Ahmad Bengaluru
In order to meet the growing demand of life-saving drug remdesivir to treat Covid-19 patients, US headquartered pharmaceutical company Mylan has launched the product under the brand name Desrem.

The company has also launched a 24x7 helpline where patients and healthcare practitioners can access information about the drug and its availability.

Priced at Rs 4,800 per vial, the drug will be manufactured at the company’s state-of-the-art injectable facility in Bengaluru, which will work to service the demand in India and other export markets where Mylan has received a licence from Gilead for the commercialisation of remdesivir. 

“In the wake of increasing cases of

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in